Jeong Geum Seok, Hillman Prima F, Kang Myung-Gyun, Hwang Sungbo, Park Jong-Eun, Nam Sang-Jip, Park Daeui, Kim Hoon
Department of Pharmacy, Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Korea.
Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, Korea.
J Fungi (Basel). 2021 Oct 18;7(10):876. doi: 10.3390/jof7100876.
Using 126 endogenous lichen fungus (ELF) extracts, inhibitory activities against monoamine oxidases (MAOs) and cholinesterases (ChEs) were evaluated. Among them, extract ELF29 of the endogenous fungus of the lichen showed the highest inhibitory activity against hMAO-A. Compounds alternariol (AT), 5'-hydroxy-alternariol (HAT), and mycoepoxydiene (MED), isolated from the extract, had potent inhibitory activities against hMAO-A with IC values of 0.020, 0.31, and 8.68 µM, respectively. AT, HAT, and MED are reversible competitive inhibitors of hMAO-A with K values of 0.0075, 0.116, and 3.76 µM, respectively. The molecular docking studies suggested that AT, HAT, and MED had higher binding affinities for hMAO-A (-9.1, -6.9, and -5.6 kcal/mol, respectively) than for hMAO-B (-6.3, -5.2, and -3.7 kcal/mol, respectively). The relative tight binding might result from a hydrogen bond interaction of the three compounds with a Tyr444 residue in hMAO-A, whereas no hydrogen bond interaction was proposed in hMAO-B. In silico pharmacokinetics, the three compounds showed high gastrointestinal absorption without violating Lipinski's five rules, but only MED showed high probability to cross the blood-brain barrier. These results suggest that AT, HAT, and MED are candidates for treating neuropsychiatric disorders, such as depression and cardiovascular disease.
使用126种内生地衣真菌(ELF)提取物,评估了它们对单胺氧化酶(MAO)和胆碱酯酶(ChE)的抑制活性。其中,地衣内生真菌的提取物ELF29对人源单胺氧化酶A(hMAO-A)表现出最高的抑制活性。从该提取物中分离出的化合物交替链格孢酚(AT)、5'-羟基交替链格孢酚(HAT)和真菌环氧二烯(MED)对hMAO-A具有强效抑制活性,IC值分别为0.020、0.31和8.68 μM。AT、HAT和MED是hMAO-A的可逆竞争性抑制剂,K值分别为0.0075、0.116和3.76 μM。分子对接研究表明,AT、HAT和MED对hMAO-A的结合亲和力(分别为-9.1、-6.9和-5.6 kcal/mol)高于对人源单胺氧化酶B(hMAO-B)的结合亲和力(分别为-6.3、-5.2和-3.7 kcal/mol)。这种相对紧密的结合可能是由于这三种化合物与hMAO-A中的Tyr444残基形成了氢键相互作用,而在hMAO-B中未发现氢键相互作用。在计算机模拟药代动力学中,这三种化合物显示出高胃肠道吸收,且未违反Lipinski五规则,但只有MED显示出高概率穿过血脑屏障。这些结果表明,AT、HAT和MED是治疗神经精神疾病(如抑郁症和心血管疾病)的候选药物。